These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37306554)

  • 21. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
    Lee L; Ramos-Alvarez I; Moody TW; Mantey SA; Jensen RT
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118625. PubMed ID: 31862538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.
    Ren XR; Wang J; Osada T; Mook RA; Morse MA; Barak LS; Lyerly HK; Chen W
    Breast Cancer Res; 2015 Feb; 17(1):20. PubMed ID: 25849870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?
    Rossi S; Finocchiaro G; Marchetti S; Toschi L; Santoro A
    Immunotherapy; 2018 Apr; 10(5):403-410. PubMed ID: 29473467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world disease burden and outcomes of brain metastases in
    Nadler E; Espirito JL; Pavilack M; Baidoo B; Fernandes A
    Future Oncol; 2020 Aug; 16(22):1575-1584. PubMed ID: 32495656
    [No Abstract]   [Full Text] [Related]  

  • 27. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
    Momeny M; Saunus JM; Marturana F; McCart Reed AE; Black D; Sala G; Iacobelli S; Holland JD; Yu D; Da Silva L; Simpson PT; Khanna KK; Chenevix-Trench G; Lakhani SR
    Oncotarget; 2015 Feb; 6(6):3932-46. PubMed ID: 25668816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice.
    Zhang SR; Zhu LC; Jiang YP; Zhang J; Xu RJ; Xu YS; Xia B; Ma SL
    Acta Pharmacol Sin; 2017 Feb; 38(2):233-240. PubMed ID: 27840411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis.
    Breindel JL; Haskins JW; Cowell EP; Zhao M; Nguyen DX; Stern DF
    Cancer Res; 2013 Aug; 73(16):5053-65. PubMed ID: 23794705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
    Haikala HM; Lopez T; Köhler J; Eser PO; Xu M; Zeng Q; Teceno TJ; Ngo K; Zhao Y; Ivanova EV; Bertram AA; Leeper BA; Chambers ES; Adeni AE; Taus LJ; Kuraguchi M; Kirschmeier PT; Yu C; Shiose Y; Kamai Y; Qiu Y; Paweletz CP; Gokhale PC; Jänne PA
    Cancer Res; 2022 Jan; 82(1):130-141. PubMed ID: 34548332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
    Hsieh AC; Moasser MM
    Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.
    Yoshida H; Kim YH; Iwatsubo S; Sakaguchi C; Sakamori Y; Nagai H; Ozasa H; Mio T; Hirai T
    Oncology; 2020; 98(7):460-467. PubMed ID: 32222702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.
    Lombardi G; Di Stefano AL; Farina P; Zagonel V; Tabouret E
    Cancer Treat Rev; 2014 Sep; 40(8):951-9. PubMed ID: 24909312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
    Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA
    Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance.
    Chen LJ; Li XY; Zhao YQ; Liu WJ; Wu HJ; Liu J; Mu XQ; Wu HB
    Pathol Res Pract; 2017 Aug; 213(8):882-888. PubMed ID: 28688608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prospect of patritumab for treating non-small cell lung cancer.
    Horinouchi H
    Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
    Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.